Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Havas Health acquires London-based PR shop

Havas Health acquires London-based PR shop

Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

Myelin acquires agencies in Chicago and Atlanta

Myelin acquires agencies in Chicago and Atlanta

Fourth and fifth members of network add healthcare advertising and PR expertise.

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Treato bolsters social-media insight

The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.

BMS combo would gain heft in melanoma space, say analysts

BMS combo would gain heft in melanoma space, say analysts

The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Five things for pharma marketers to know: Monday, June 22

Five things for pharma marketers to know: Monday, June 22

AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.

Grand Prix drought ends, but questions persist

Grand Prix drought ends, but questions persist

The inspirational value is clear for Lions Health attendees, but there is still confusion about what good looks like for branded pharma campaigns, and how the US fits in.

Pharma at Cannes: C'est la Vie

Pharma at Cannes: C'est la Vie

It's not only a venue to gain creative inspiration, but a good place to scout talent, and there are no lack of strategic meetings underway in Cannes.

Mobile's role in healthcare is still experimental

Mobile's role in healthcare is still experimental

Mobile app makers shared insights about how to improve people's health and change behavior at the Lions Health festival.

Mullen Lowe's Sokoloff closes Lions Health

The second annual Lions Health creativity festival ended Saturday.

Novartis exec: Pharma culture can be stumbling block to creativity

Novartis exec: Pharma culture can be stumbling block to creativity

It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca's "Take it from a Fish" took the top prize.

Five things for pharma marketers to know: Friday, June 19

Five things for pharma marketers to know: Friday, June 19

Teva loses Copaxone patent suit; Oncologists at Memorial Sloan Kettering Cancer Center developed cancer drug cost calculator; Bayer will invest $4.5 billion in R&D in the coming year.

19 US entries shortlisted at Lions Health

19 US entries shortlisted at Lions Health

The Lions Health award winners will be announced later Friday at an event in Cannes, France.

Campbell Ewald replaces Weber Shandwick on $50m-a-year Covered California account

Campbell Ewald replaces Weber Shandwick on $50m-a-year Covered California account

The health benefits exchange also retained Ogilvy Public Relations for its $2-million-a-year communications account, PRWeek reported.

Doximity expands professional reach

Its alliance with the Society of Hospital Medicine will expand the network's reach among medical professionals.

Fitbit IPO spurs questions about relevance to healthcare

The activity monitor dominates the fitness market, but competition in the overall health category is increasing.

Takeda revamps commercial org to synch with R&D

Takeda revamps commercial org to synch with R&D

The Japan-based drugmaker recast its global organization in hopes of ensuring that emerging molecules make a smoother transition to market.

EY launches health innovation incubator

The effort is part of the consultancy's Startup Challenge that pairs health neophytes with mentors.

Ogilvy CommonHealth Worldwide—O'Neill and Price (Skill Sets Live)

MM&M news editor Jaimy Lee talks with Paul O'Neill, president, and Mindy Price, group planning director of Ogilvy CommonHealth Worldwide to discuss the fundamental changes affecting the healthcare consumer.

GlaxoSmithKline (Skill Sets Live)

MM&M news editor Jaimy Lee sits down with the Jim DeLash, director, multi-channel marketing, GlaxoSmithKline to dicuss customer segmentation and the new definition of multi-channel marketing.

Athenahealth (Skill Sets Live)

MM&M news editor Jaimy Lee sits down with Heather Gervais, Athenahealth vice president of commercial sponsorship to discuss the top trends in the healthcare landscape.

Ogilvy CommonHealth Worldwide—Patel (Skill Sets Live)

MM&M news editor Jaimy Lee sits down with Ritesh Patel, chief digital officer of Ogilvy CommonHealth Worldwide to discuss the impact of mobile and apps on healthcare marketers.

Five things for pharma marketers to know: Thursday, June 18

Five things for pharma marketers to know: Thursday, June 18

Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year

MM&M's guide to the sessions at Lions Health

MM&M's guide to the sessions at Lions Health

Advice for the healthcare marketing neophyte and veteran alike on making the most of the sessions at the Palais des Festivals during Lions Health June 19-20.

Agency leaders share advice on how to navigate Lions Health

Agency leaders share advice on how to navigate Lions Health

The annual creativity festival kicks off on Friday for the pharma and health-focused Lions Health event.

Lilly moves to bolster its oncology pipeline

Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute signed on to help the drugmaker develop cancer treatments.

Drug pricing drives debates at BIO convention

Drug pricing drives debates at BIO convention

Drugmakers, experts discuss strategies to cope with costly new drugs.

Five things for pharma marketers to know: Wednesday, June 17

Five things for pharma marketers to know: Wednesday, June 17

Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020

Study shows pharma compensates genders differently

Study shows pharma compensates genders differently

A dive into financial relationships between industry and doctors showed women receive less money for research, education and speaking than men.

Clinton tells pharma to explain drug prices

Clinton tells pharma to explain drug prices

Speakers at Klick Health's event criticized, lauded the role of technology in healthcare.

Bayer and Johns Hopkins University ink eye-disease research collaboration

The drugmaker and university will work together to develop new treatments for eye-related diseases like age-related macular degeneration.

Five things for pharma marketers to know: Tuesday, June 16

Five things for pharma marketers to know: Tuesday, June 16

Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs

Amicus briefs pile up in Amarin lawsuit

The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.

Survey shows doctors ready for PCSK9s

Survey shows doctors ready for PCSK9s

Cardiologists are more likely to prescribe the experimental drugs than are primary-care physicians.

Five things for pharma marketers to know: Monday, June 15

Five things for pharma marketers to know: Monday, June 15

CVS Health to buy Target's pharmacy business; experimental gene therapy improves condition of teen with sickle-cell disease; PatientsLikeMe partners with the FDA to improve postmarket surveillance

Five things for pharma marketers to know: Friday, June 12

Five things for pharma marketers to know: Friday, June 12

PhRMA files amicus brief in support of Amarin's off-label lawsuit; Public Citizen argues FDA wrongly expanded indication for Hetlioz; FDA panel recommends GSK's new asthma treatment for approval

Amarin lawsuit about more than fish oil

Amarin lawsuit about more than fish oil

An FDA letter says there was no need to go to court but experts tell MM&M this lawsuit highlights an issue that is bigger than a single pill.

Public health officials to distribute Truvada in fight against HIV

Los Angeles County voted in favor of adding the drug to the public health program's repertoire in fighting HIV and AIDS.

Five things for pharma marketers to know: Thursday, June 11

Five things for pharma marketers to know: Thursday, June 11

Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups

Pioneering info portal for doctors turns 20

Pioneering info portal for doctors turns 20

Medscape marked its 20th anniversary with a reunion this week that attracted staffers from the portal's earliest days.

Pfizer's "Get Old" campaign gets youthful

Pfizer's "Get Old" campaign gets youthful

The three-year-old campaign's youthful tone evolves as its audience ages.

Roche sclerosis drug granted Breakthrough Therapy status

Roche's Actemra is already approved for three forms of arthritis.

Five things for pharma marketers to know: Wednesday, June 10

Five things for pharma marketers to know: Wednesday, June 10

FDA panel recommends Sanofi/Regeneron's PCSK9 inhibitor for approval; Merck and Samsung collaboration says their rheumatoid arthritis biosimilars are equivalent to the biologic versions; Bayer offloads its diabetes-care business

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

Lions Health entries increase by 30% in 2015

A quarter of this year's 1,862 entries are in the pharma category.

GSK asthma medication to go before FDA panel Thursday

GSK asthma medication to go before FDA panel Thursday

There has been little talk about mepolizumab but an approval would fill out GSK's flagging respiratory category.

Sanofi will resubmit lixisenatide to FDA

The drugmaker's once-daily diabetes treatment, lixisenatide, will be sent back to US regulators after Sanofi pulled the submission in 2013 to finish a cardiovascular outcomes trial.

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

PCSK9 adcomm preview: what's at stake

PCSK9 adcomm preview: what's at stake

An FDA advisory committee will sound off on the future of cholesterol-lowering treatments this week, discussing if Sanofi/Regeneron's Praluent and Amgen's Repatha warrant marketing approval.

Everyday Health names new EVP

Jed Savage replaces Scott Wolf.

Lilly says peglispro is superior to Sanofi's Lantus

Concerns persist regarding the drug's impact on liver enzymes and fat.

A Q&A with Sir Roger Moore, 2015 Young Lions Health Award judge

A Q&A with Sir Roger Moore, 2015 Young Lions Health Award judge

Moore, a longtime Goodwill Ambassador for Unicef, talked with MM&M about how creativity can be used to improve public health.

Five things for pharma marketers to know: Monday, June 8

Five things for pharma marketers to know: Monday, June 8

Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain

Five things for pharma marketers to know: Friday, June 5

Five things for pharma marketers to know: Friday, June 5

FDA panel recommends approval of female Viagra; FDA says that Sanofi's and Regeneron's PCSK9 inhibitor lowers LDL; GSK cuts 350 jobs

DTC expected to propel Afrezza awareness, not necessarily sales

DTC expected to propel Afrezza awareness, not necessarily sales

Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.

A Patient Journey Isn't the Solution to Pharma Marketing—It's the Beginning

A Patient Journey Isn't the Solution to Pharma Marketing—It's the Beginning

We need to view the patient journey as a starting place for much deeper analysis.

Four Communications acquires MSA Media

UK indie shop buys healthcare specialist agency to strengthen media-planning business.

FDA grants Breakthrough status to Niemann-Pick drug

Genzyme's experimental enzyme-replacement therapy olipudase alfa is being investigated for the Type B form of the condition.

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Study: Patients with marketplace health plans spend less on medications

Study: Patients with marketplace health plans spend less on medications

Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.

Five things for pharma marketers to know: Wednesday, June 3

Five things for pharma marketers to know: Wednesday, June 3

Teva is planning to up its stake in Mylan prior to a possible legal challenge; Perrigo acquires GSK OTC portfolio; Express Scripts considers creative ways to drive down drug costs

APCO, Text100 launch health technology group

APCO, Text100 launch health technology group

The new initiative, ATDigitalHealth, will help healthcare companies with disruptive concepts win over decision-makers.

Patient advocacy groups say pharma needs to be a better partner

Patient advocacy groups say pharma needs to be a better partner

An inVentiv Health study indicates patient groups want more say in drug development and patient support.

Five things for pharma marketers to know: Tuesday, June 2

Five things for pharma marketers to know: Tuesday, June 2

A House committee is looking into the FDA's warning letter publication process; Amgen and Roche collaborate on cancer combination drug; study shows online health information fails teenagers

Genentech game invites players to attack cancer

The first of seven games aimed at teaching about immuno-oncology lets players fling antibodies at cancer cells.

GSK's Flonase tops allergy category

The new OTC medication almost hit $100 million in sales in its first 16 weeks on the market.

Cannes Grand Prix may again prove elusive for pharma

Cannes Grand Prix may again prove elusive for pharma

The Lions Health jurors in 2014 declined to award the top prize in the pharma category, raising questions about how the industry's creativity stacks up against the world's top marketers.

A Q&A with Rob Rogers, 2015 Lions Health pharma jury president

A Q&A with Rob Rogers, 2015 Lions Health pharma jury president

He spoke with MM&M about whether pharma is ready to win a Grand Prix, if regulation limits creativity in healthcare, and why wearables may spur creativity.

In their words: the most inspirational speakers at the 2014 Lions Health

An MM&M roundup of what the festival's most inspirational speakers had to say about creativity in healthcare and challenges like talent recruitment and implementing digital innovation.

Five things for pharma marketers to know: Monday, June 1

Five things for pharma marketers to know: Monday, June 1

Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics

Key Moments

Key Moments

A timeline of important milestones in the era of patient engagement

Five things for pharma marketers to know: Friday, May 29

Five things for pharma marketers to know: Friday, May 29

Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015

Teva settles pay-for-delay case for $1.2 billion

Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.

Five things for pharma marketers to know: Thursday, May 28

Five things for pharma marketers to know: Thursday, May 28

The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate

Mango Health takes on chronic conditions

Mango Health takes on chronic conditions

The updated app now tracks everyday health metrics including weight, activity and glucose levels.

Therapeutic Focus: Infectious Diseases

Therapeutic Focus: Infectious Diseases

While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

New bill seeks to spur FDA to form clearer social media rules

New bill seeks to spur FDA to form clearer social media rules

Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

NPs expand right to practice independently

Twenty states now allow nurse practitioners to practice without an MD affiliation.

ASCO preview: What's coming for lung cancer

ASCO preview: What's coming for lung cancer

A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.

Court orders Actavis to keep Namenda IR on market

An appeals court affirmed an earlier ruling that Actavis must keep an older formulation of its Alzheimer's drug, Namenda, on the market.

J&J puts global media business up for review

J&J puts global media business up for review

The review does not include North America, the healthcare giant said.

Five things for pharma marketers to know: Tuesday, May 26

Five things for pharma marketers to know: Tuesday, May 26

Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications

Five things for pharma marketers to know: Friday, May 22

Five things for pharma marketers to know: Friday, May 22

Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.

OPDP finds fault with Rapaflo website

The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.

UCLA looks to Twitter for health trends

UCLA looks to Twitter for health trends

Researchers say Twitter could provide critical insight into health needs for hard-to-reach groups.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.